Fleck C, Karabinos A, Cook A, Moore DC, et al. Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
PMID: 38646879